Abstract
The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies. To assess the overall absolute beneficial and/or harmful impact of aspirin and clopidogrel combination therapy compared with monotherapy with either drug, we analyzed the results from both trials in terms of number needed to treat per year. Treating between 35 and 204 at-risk patients for 1 year with combination therapy appeared to prevent 1 patient from experiencing an adverse primary cardiovascular outcome; whereas, about 1 in 63 such patients appeared liable to major bleeding during that period. We determined that the evidence to date indicates no overall advantage for combination therapy with anti-platelet drugs in preference to monotherapy.
MeSH terms
-
Angina, Unstable / drug therapy*
-
Arteriosclerosis / drug therapy*
-
Aspirin / administration & dosage
-
Aspirin / adverse effects*
-
Aspirin / therapeutic use*
-
Clopidogrel
-
Cyclooxygenase Inhibitors / administration & dosage
-
Cyclooxygenase Inhibitors / adverse effects*
-
Cyclooxygenase Inhibitors / therapeutic use*
-
Double-Blind Method
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Humans
-
Placebos
-
Platelet Aggregation Inhibitors / administration & dosage
-
Platelet Aggregation Inhibitors / adverse effects*
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Recurrence
-
Thrombosis / drug therapy*
-
Ticlopidine / administration & dosage
-
Ticlopidine / adverse effects*
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / therapeutic use*
-
Treatment Outcome
Substances
-
Cyclooxygenase Inhibitors
-
Placebos
-
Platelet Aggregation Inhibitors
-
Clopidogrel
-
Ticlopidine
-
Aspirin